DALLAS, Aug. 24, 2009 (GLOBE NEWSWIRE) -- StockPreacher.com announces an investment report featuring stem cell company Advanced Cell Technology Inc. (Pink Sheets:ACTC). The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.
The investment report on Advanced Cell Technology Inc. (Pink Sheets:ACTC) should be of particular interest to other stem cell-based therapeutics developers: StemCells Inc. (Nasdaq:STEM), Neuralstem Inc. (AMEX:CUR), Geron Corp. (Nasdaq:GERN) and Cytori Therapeutics Inc. (Nasdaq:CYTX).
It is available at: http://www.stockpreacher.com/n/ACTC
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/StockPreacher
Advanced Cell Technology Inc. (ACTC) focuses on the development and commercialization of human embryonic and adult stem cell technology in the emerging fields of regenerative medicine and stem cell therapy. The Company's technologies could provide therapies for broad range of diseases, including myoblasts for treating heart failure; hemangioblasts for treating blood disorders, cardiovascular disease and cancer; retinal pigment epithelial cells for treating macular degeneration and other retinal degenerative disorders; skin cells for dermatological conditions; neuronal cells for spinal cord injury; and liver cells for hepatitis and cirrhosis.
In the report, the analyst notes:
"On top of recent development in its focus programs, ACTC developed and demonstrated a significant technique to generate embryonic stems that maintain developmental potential of the embryo ... the Company owns or licenses more than 380 patents and patent applications related to stem cell therapy. In its recent 10-Q, the Company attributed the increase in revenue for the second quarter of 2009 to more new licenses being granted, as compared to the same period last year.
"ACTC Chief Scientific Officer Dr. Robert Lanza was recently featured on Deepak Chopra's Wellness Radio. On the show, Dr. Lanza discussed the cutting edge of regenerative medicine, including the Company's efforts to use stem cells to treat blindness, vascular damage and heart disease ..."
To read the entire report visit: http://www.stockpreacher.com/n/ACTC
See what investors are saying about these stocks at: http://www.stockhideout.com/
StockPreacher.com is a small-cap research and investment commentary provider. StockPreacher.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on StockPreacher, please visit: http://www.stockpreacher.com
StockPreacher.com Disclosure
StockPreacher.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. StockPreacher.com is a Web site wholly-owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, StockPreacher.com, for complete risks and disclosures.